M&A Deal Summary |
|
---|---|
Date | 2016-08-08 |
Target | SCILEX Pharmaceuticals |
Sector | Life Science |
Buyer(s) | Sorrento Therapeutics |
Deal Type | Add-on Acquisition |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 2006 |
Sector | Life Science |
Employees | 949 |
Revenue | 63M USD (2022) |
Sorrento Therapeutics is an oncology company that is involved in the development of small molecules, mono- and bi-specific antibodies and antibody drug conjugates for treatment of cancer and associated pain. Sorrento Therapeutics was founded in 2006 and is based in San Diego, California.
DEAL STATS | # |
---|---|
Overall | 3 of 9 |
Sector (Life Science) | 3 of 9 |
Type (Add-on Acquisition) | 3 of 7 |
State (Pennsylvania) | 1 of 1 |
Country (United States) | 3 of 8 |
Year (2016) | 1 of 2 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2015-05-15 |
IgDraSol
Fountain Valley, California, United States IgDraSol, Inc. is a pharamaceutal company focused on the development of oncologic agents for the treatment of metastatic breast cancer (“MBC”), non-small cell lung cancer (“NSCLC”), and other cancers. |
Sell | - |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2016-08-15 |
Semnur Pharmaceuticals
Los Altos, California, United States Semnur Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the clinical and commercial development of innovative products that meet the needs of pain management practitioners and their patients. Semnur's primary focus lies in the development of non-opioid products for meeting the needs of underserved patients with back pain. Semnur believes that the therapeutic advantages of their product and technology will improve products' efficacy and safety making a substantial improvement in the treatment of back pain. |
Buy | - |